Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gritstone Oncology Inc (GRTS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 401,126
  • Shares Outstanding, K 29,194
  • Annual Sales, $ 1,190 K
  • Annual Income, $ -64,780 K
  • 60-Month Beta N/A
  • Price/Sales 341.87
  • Price/Cash Flow N/A
  • Price/Book 2.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.72
  • Number of Estimates 2
  • High Estimate -0.62
  • Low Estimate -0.81
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.78 +40.47%
on 03/25/19
15.94 -13.80%
on 04/05/19
+0.40 (+3.00%)
since 03/18/19
3-Month
9.66 +42.24%
on 03/14/19
16.04 -14.34%
on 01/23/19
-1.86 (-11.92%)
since 01/18/19

Most Recent Stories

More News
Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Eugene Zhukovsky,...

GRTS : 13.74 (-1.15%)
Gritstone Oncology to Present at Needham Healthcare Conference

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D.,...

GRTS : 13.74 (-1.15%)
Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE(TM) Significantly Outperforms Current Prediction Methods

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the presentation...

GRTS : 13.74 (-1.15%)
Gritstone Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results...

GRTS : 13.74 (-1.15%)
Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the first patient...

GRTS : 13.74 (-1.15%)
Gritstone Oncology Announces the Appointment of Technology Executive, Mike Forcht, as Senior Vice President of Human Resources to Support Vision for Growth

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Mike Forcht,...

GRTS : 13.74 (-1.15%)
Gritstone Oncology to Present at Two Upcoming Investor Conferences in March

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D.,...

GRTS : 13.74 (-1.15%)
Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D.,...

JPM : 113.46 (-0.73%)
GRTS : 13.74 (-1.15%)
Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the U.S. Food...

GRTS : 13.74 (-1.15%)
TCR2 Therapeutics Announces Oncology Industry Leader and Expert Andrew Allen, M.D., Ph.D. Joins its Board of Directors

TCR2 Therapeutics Inc., an innovative immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced the appointment of...

GRTS : 13.74 (-1.15%)
FSNN : 0.24 (+3.57%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade GRTS with:

Business Summary

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict...

See More

Key Turning Points

2nd Resistance Point 14.54
1st Resistance Point 14.14
Last Price 13.74
1st Support Level 13.47
2nd Support Level 13.20

See More

52-Week High 32.90
Fibonacci 61.8% 24.02
Fibonacci 50% 21.28
Fibonacci 38.2% 18.54
Last Price 13.74
52-Week Low 9.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar